Daily Cardiology Research Analysis
Three impactful cardiology papers span basic-to-clinical translation: an engineered adeno-associated virus targeting pulmonary arterial smooth muscle cells reverses pulmonary arterial hypertension in rodents; ARID5A is identified as a key RNA-binding regulator of human cardiac aging via MAVS mRNA stabilization, with therapeutic knockdown improving function in mice; and the CALIPSO randomized trial shows OCT-guided PCI with algorithmic planning achieves larger stent expansion in calcified lesions
Summary
Three impactful cardiology papers span basic-to-clinical translation: an engineered adeno-associated virus targeting pulmonary arterial smooth muscle cells reverses pulmonary arterial hypertension in rodents; ARID5A is identified as a key RNA-binding regulator of human cardiac aging via MAVS mRNA stabilization, with therapeutic knockdown improving function in mice; and the CALIPSO randomized trial shows OCT-guided PCI with algorithmic planning achieves larger stent expansion in calcified lesions without added safety risk.
Research Themes
- Targeted gene therapy for pulmonary vascular disease
- RNA-binding proteins and inflammaging in cardiac aging
- Imaging-guided optimization of calcified coronary PCI
Selected Articles
1. A highly mobile adeno-associated virus targeting vascular smooth muscle cells for the treatment of pulmonary arterial hypertension.
Directed-evolution produced a highly mobile, PASMC-tropic AAV that traverses airway-to-vascular barriers. Intratracheal delivery of FGF12 cargo suppressed pulmonary vascular remodeling, prevented PAH in mice, and reversed established PAH in rats, supporting a disease-modifying gene therapy strategy.
Impact: This is a first-in-class vector solution enabling PASMC-specific gene delivery via airways with efficacy in prevention and reversal of PAH in vivo, addressing a major translational barrier in pulmonary vascular therapeutics.
Clinical Implications: If safety and biodistribution are confirmed in large animals and humans, intratracheal PASMC-targeted gene therapy could offer a disease-modifying or curative option for PAH beyond current vasodilators.
Key Findings
- Engineered a highly mobile, PASMC-tropic AAV via directed evolution that crosses airway-to-vascular barriers.
- Intratracheal AAV-FGF12 suppressed pulmonary vascular remodeling and prevented PAH development in mice.
- The same approach reversed established PAH in rat models, demonstrating therapeutic potential in advanced disease.
Methodological Strengths
- Rational vector engineering with in vivo validation across mouse and rat PAH models.
- Target-cell (PASMC) specificity and airway delivery enabling clinically feasible administration.
Limitations
- Preclinical animal data; human immunogenicity, off-target tropism, and long-term safety are unknown.
- Durability of transgene expression and re-dosing feasibility were not fully characterized.
Future Directions: Conduct large-animal biodistribution/toxicity studies, optimize dosing and re-dosing strategies, and initiate early-phase clinical trials; explore alternative cargos and combination with vasodilators.
In pulmonary arterial hypertension (PAH), a phenotypic switch in pulmonary arterial smooth muscle cells (PASMCs) that is primarily caused by aberrant gene regulatory networks can lead to dysregulated vascular remodelling, heart failure or death. No curative therapies for PAH are currently available, presumably because of a lack of viral vectors specifically targeting PASMCs. Here we show that a highly mobile and PASMC-tropic adeno-associated virus variant developed via directed evolution overcomes physical barriers that inhibit its transfer from bronchial airways to vascular layers, ultimately boosting therapeutic efficacy in murine models of PAH. Intratracheal administration of the adeno-associated virus variant carrying a transgene for fibroblast growth factor 12-a key factor regulating the PASMC phenotype-suppressed pulmonary vascular remodelling, prevented the development of PAH in mice and reversed established PAH in rats. The variant's mobility and enhanced tropism for PASMCs may enable curative treatments for PAH.
2. ARID5A orchestrates cardiac aging and inflammation through MAVS mRNA stabilization.
Single-cell multi-omics of 74 human hearts identified inflammaging driven by upregulated ARID5A. ARID5A stabilizes MAVS mRNA, activating NF-κB/TBK1. Myocardial ARID5A knockdown in aged mice reduced inflammatory/aging phenotypes and improved function, nominating the ARID5A–MAVS axis as a therapeutic target.
Impact: Defines a post-transcriptional RNA-binding mechanism for human cardiac aging using human tissue and demonstrates therapeutic modulation in vivo.
Clinical Implications: Targeting ARID5A or the MAVS stabilization pathway could attenuate cardiac inflammaging and preserve function, motivating development of small-molecule or RNA therapeutics.
Key Findings
- Human single-cell transcriptomics across 74 hearts identified ARID5A upregulation as a key driver of inflammaging.
- ARID5A stabilizes MAVS mRNA, activating NF-κB and TBK1 to amplify aging/inflammatory phenotypes.
- Lentiviral shRNA-mediated myocardial ARID5A knockdown in aged mice reduced inflammation/aging markers and improved cardiac function.
Methodological Strengths
- Use of human cardiac tissue spanning age spectrum with single-cell resolution and multi-omic integration.
- Mechanistic validation with in vivo gene therapy knockdown demonstrating functional benefit.
Limitations
- Human analyses are cross-sectional; causality relies on animal knockdown models.
- Long-term safety and translatability of ARID5A inhibition in large animals/humans remain unknown.
Future Directions: Develop selective ARID5A modulators, map tissue-specific effects, assess safety/efficacy in large-animal models, and explore biomarkers of ARID5A–MAVS activity for patient stratification.
Elucidating the regulatory mechanisms of human cardiac aging remains a great challenge. Here, using human heart tissues from 74 individuals ranging from young (≤35 years) to old (≥65 years), we provide an overview of the histological, cellular and molecular alterations underpinning the aging of human hearts. We decoded aging-related gene expression changes at single-cell resolution and identified increased inflammation as the key event, driven by upregulation of ARID5A, an RNA-binding protein. ARID5A epi-transcriptionally regulated Mitochondrial Antiviral Signaling Protein (MAVS) mRNA stability, leading to NF-κB and TBK1 activation, amplifying aging and inflammation phenotypes. The application of gene therapy using lentiviral vectors encoding shRNA targeting ARID5A into the myocardium not only mitigated the inflammatory and aging phenotypes but also bolstered cardiac function in aged mice. Altogether, our study provides a valuable resource and advances our understanding of cardiac aging mechanisms by deciphering the ARID5A-MAVS axis in post-transcriptional regulation.
3. OCT vs Angiography for Guidance of Percutaneous Coronary Intervention of Calcified Lesions: The CALIPSO Randomized Clinical Trial.
In 134 analyzable patients with calcified coronary lesions, OCT-guided PCI using predefined algorithms achieved significantly larger minimal stent area than angiography guidance (median 6.5 vs 5.0 mm²; P<.001) without increasing periprocedural complications, contrast volume, or procedure time.
Impact: First randomized evaluation showing algorithmic OCT guidance improves stent expansion in calcified lesions, a frequent and challenging PCI subset.
Clinical Implications: Supports adopting OCT-guided planning and lesion preparation algorithms for calcified lesion PCI to optimize stent expansion; larger outcome-driven trials and cost-effectiveness analyses are warranted.
Key Findings
- OCT-guided PCI produced a larger post-PCI minimal stent area vs angiography (6.5 vs 5.0 mm²; P<.001).
- No increase in periprocedural MI, contrast usage, or procedure duration with OCT guidance.
- Intravascular lithotripsy use was higher in the OCT arm (46% vs 12%), consistent with algorithm-driven lesion preparation.
Methodological Strengths
- Prospective, multicenter randomized design with standardized OCT-based algorithms.
- Objective primary endpoint (MSA) assessed by OCT in both arms post-PCI.
Limitations
- Open-label trial with a surrogate imaging endpoint and modest sample size.
- Short-term assessment; no clinical outcomes (e.g., TLF/MACE) powered analyses.
Future Directions: Conduct larger trials powered for clinical endpoints (MACE/TLF), evaluate cost-effectiveness and workflow, and define operator training/learning curves for algorithmic OCT guidance.
IMPORTANCE: The use of intravascular imaging for calcified plaque characterization and preparation has been advocated over conventional methods to improve percutaneous coronary intervention (PCI) outcomes, but this approach has never been evaluated. OBJECTIVE: To determine if optical coherence tomography (OCT) is superior to angiography for calcified lesions PCI guidance. DESIGN, SETTING, AND PARTICIPANTS: The CALIPSO (Calcified Lesion Intervention Planning Steered by OCT) trial was a prospective, multicenter, open-label, randomized clinical trial that included patients with stable moderate to severe calcified coronary lesions on coronary angiography scheduled for PCI. The trial was conducted at 12 sites in France between December 2021 and June 2023, and data were analyzed from December 2023 to April 2024. INTERVENTION: After diagnostic coronary angiography, eligible patients were randomly assigned in a 1:1 ratio to receive OCT-guided PCI or angiography-guided PCI. In the OCT group, the procedures were guided by OCT analysis and predefined standardized management algorithms. Patients from both arms had control post-PCI OCT analysis after procedure completion for primary end point measurement. MAIN OUTCOMES AND MEASURES: The primary end point was the minimal stent area (MSA) measured by OCT in both groups. Secondary key safety end points included periprocedural myocardial infarction, radiation dose, contrast medium volume, and procedure duration. RESULTS: A total of 143 patients were randomized, and 134 were included in the final analysis (65 in the OCT group and 69 in the angiography group). Median (IQR) patient age was 73.0 (66.0-78.0) years, and 25 patients (18.7%) were female. The baseline characteristics of the groups were comparable, but the use of intravascular lithotripsy was more frequent in the OCT arm (30 patients [46%] vs 8 patients [12%]; P < .001). The final median (IQR) MSA was larger in the OCT group than in the angiography group (6.5 [5.5-8.1] mm2 vs 5.0 [4.1-6.1] mm2; P < .001). There was no difference in periprocedural complications incidence, contrast medium volume, or procedure duration between groups. CONCLUSIONS AND RELEVANCE: The CALIPSO randomized clinical trial showed that OCT guidance associated with predefined algorithmic management achieved better stent implantation results than angiography guidance in patients with calcified lesions PCI, without any additional safety concern. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05301218.